Zinc and essential fatty acid status and supplementation in cystic fibrosis patients by Van Biervliet, Stephanie
Tijdschrift van de Belgische Kinderarts • 2008 - Vol. 10 - Nr.3     64 Journal du Pédiatre Belge •  2008 - Vol. 10 - Nr.3    65
Made in Belgium
Zinc and essential fatty acid status and 
supplementation in cystic fibrosis patients
To evaluate the Zn status one can use the serum Zn 
concentration. However, there are some limitations, since the 
Zn concentration remains normal for a long period despite 
insufficient intake. Further on, there is a diurnal variation, 
with the highest Zn value in the morning. Serum Zn will also 
decrease in case of inflammation. Further on one can use Zn 
dependant enzymes, as e.g. alkaline phosphatase, to evaluate 
the Zn status. Finally the best way to evaluate is a double blind, 
placebo controlled supplementation study.
Fatty acids (FA) are carbon chains divided in saturated, 
monounsaturated or polyunsatured, depending on the number 
of double bounds in the carbon chain. The first double binding 
from the methyl end on will indicate the family they belong to: 
omega 3, 6, 7 or 9 fatty acids. 
Omega 3 alfalinolenic acid (ALA) and omega 6 linoleic acid 
(LA) are essential for the human being since they cannot be 
synthesized by the human body and are needed for correct 
cellular functioning. 
The FAs can be elongated and desaturated into the different 
FAs of their family. 
However, these long chain polyunsaturated FAs can also be 
present in some food elements. 
The functions of FAs are energy source and reserve. They 
are important for the biomembrane structure. The fluidity of 
the membrane will be dependent of the amount of long chain 
polyunsaturated FAs. FAs have also direct influences on the 
membrane protein functions. Finally, some of them are the 
precursors of eicosanoids and docosanoids (as thromboxanes, 
prostaglandins, leukotrienes…) which are important for the 
initiation and stopping of inflammatory processes. Depending 
on the balance of the composition of FAs in membranes, there 
will be more or less pro-inflammatory eicosanoids produced. 
Arachidonic acid (AA) is the FA producing the most important 
proinflammatory eicosanoids. The ″3 eicosapentaenoic 
acid (EPA) and ″6 dihomogammalinoleic acid (DHGLA) are 
precursors of less pro-inflammatory or even anti-inflammatory 
eicosanoids.
The FA status can be evaluated by determination of serum FAs. 
To decrease the impact of recent nutrition the most reliable 
  Introduction
Cystic fibrosis (CF) is an autosomal recessive disease 
caused by a mutation in the CF Transmembrane Conductance 
Regulator (CFTR) located on chromosome 7. CF is a 
multiorgan disease with pulmonary inflammation and infection 
as major cause of death. However, nutritional issues play an 
important role in CF care, since a better survival and slower 
pulmonary decline was demonstrated in patients with a 
normal body weight. As 90% of CF patients have exocrine 
pancreatic insufficiency, pancreatic enzyme replacement and 
fat – soluble vitamin supplementation is common practice. 
However, patient with CF might be at risk for other deficiencies 
which could also influence the clinical course of the disease. 
However, there are no sufficient research data to support 
general or selected supplementation. This thesis deals with 2 
of these elements: zinc and fatty acids. 
Zinc (Zn) is the second most abundant trace element in 
the human body. Its functions can be divided into catalytic, 
structural and regulatory. It plays an important role in enzymes, 
transcription factors, membranes, hormonal receptor sites and 
so on. Due to its importance in so many cellular functions, the 
symptoms of Zn deficiency are very general including anorexia, 
immune dysfunction, growth impairment and essential fatty 
acid disturbances. These problems are also often encountered 
in CF patients. Zn is mainly found in meat. 
Absorption will be impaired by unabsorbed fatty acids, as 
demonstrated by Krebs. Formation of unabsorbable soaps by 
zinc and unabsorbed fatty acids causes a problem in cystic 
fibrosis since many patients continue to have fat malabsorption 
despite the correct intake of pancreatic enzyme replacement 
therapy. 
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parameter is the serum phospholipid FA composition. Total 
serum FA composition is a much less reliable determination, as 
compositional differences occur due to recent dietary intake. 
In case of essential FA deficiency, the human body elongates 
and desaturates ″9 oleic acid to produce mead acid and its 
derivatives. The ratio of ″6 AA over ″3 docosahexaenoic acid 
(DHA) is thought to indicate the inflammatory aspects of the 
fatty acid profile.
There is a close interaction between essential FAs and 
Zn, which was initially speculated, based upon the similarity 
of deficiency symptoms: skin lesions, impaired growth, 
impaired wound healing and delayed sexual maturation. FA 
abnormalities were described in acrodermatitis enteropathica, 
an inherited disease of Zn absorption and in transient Zn 
deficiency. Hamilton described an association between Zn 
and AA in CF. 
Animal studies have until now not been able to elucidate the 
exact way of interaction. 
Cunane et al. postulated a desaturation defect. However, his 
results were not confirmed by others. Eder et al. proposed 
an interference with the incorporation of the FA in the 
phospholipids. Further on, an increased beta-oxidation of LA 
has been described in Zn deficiency and finally, Zn and LA will 
improve each others absorption.
Study aims:
The aim of this thesis was to evaluate the Zn and essential 
FA status in our CF population and evaluate whether 
supplementation of Zn or essential FAs could be useful for the 
clinical course of the disease.
Results:
Studies on Zn in CF:
To be able to compare the data of our CF population to local 
healthy controls, 447 healthy children were studied during 
a vaccination campaign. Our local control group [1] has a 
significantly lower serum Zn concentration than described in 
literature. 
The Zn concentration at diagnosis and after one year of 
therapy was determined in 32 newly diagnosed CF patients 
[2]. At diagnosis the Zn concentration was 10.7 µmol/L and 
12.1 after one year. Compared to the local age matched 
control group, serum Zn in CF was not different. However, 
the serum zinc concentration significantly increased after one 
year of Zn supplementation therapy. Comparing our data on 
Zn in CF with the data of NHANES II study, including more 
the 4000 children, 40% of the CF patients at diagnosis and 
12.5% after one year of therapy had serum Zn values below 
the third percentile. These results confirm the data of Krebs et 
al., observed in young CF patients. Our serum Zn values are 
comparable to theirs. 
The observed association with vitamins A and E is probably 
caused by the concurrent steatorrhoea.
Since the serum Zn concentration increases with age and 
therapy, treated CF patients were studied [3]. 101 treated CF 
patients had a Zn determination. The median Zn concentration 
was 12.2 µmol/L. The serum Zn from the older patients was 
not significantly different from our healthy controls. But again 
16.5% fall below the NHANES II references. There was an 
association of serum Zn with serum albumin, which is not 
surprising since Zn is transported on serum albumin. 
Zn interferes also in different ways in the vit A metabolism. 
It could explain its association with serum vit A levels. Since 
no association was found with serum vit E, fat malabsorption 
is probably a less important factor for the explanation of the 
relation zinc -vit A, in this treated group.
The observed association of serum Zn with the mean forced 
vital capacity was a surprising observation. 
Although speculations on better nutritional status, less 
inflammation or better immune function can be made, 
this observation merits a large prospective double blind 
supplementation study, for further confirmation of the relation 
of pulmonary function in CF and improved the Zn status.
Serum Zn is as explained the best available parameter for 
evaluation of Zn status in populations. However, a normal 
serum Zn concentration does not exclude a Zn deficiency. 
Therefore intestinal alkaline phosphatase a Zn dependant 
enzyme was studied. Intestinal alkaline phosphatase (IAP) is 
an interesting enzyme since it needs Zn or magnesium for 
its function but also its gene transcription is activated by a 
Zn containing protein. Finally, this enzyme is very sensitive for 
peroxidation. Zn deficiency, a condition prone to peroxidative 
processes, will therefore decrease the enzyme protein content 
and its activity, resulting in enzyme inactivation. 
The brush border enzyme activity of 61 newly diagnosed CF 
patients was determined [4, 5]. A damaged mucosa was 
present in 1/3 of the CF population. The controls consisted of 
children with unexplained failure to thrive. Regardless of their 
mucosal histology, CF patients have a significant decrease of 
their IAP activity. On the contrary we found decreased lactase 
activity in the CF cohort with normal mucosa.
In conclusion, there are arguments for a Zn deficiency in 
some of the CF patients. As retrospective evaluation showed 
improved clinical outcomes in Zn supplemented patients, a 
prospective study is urgently needed.
Studies on essential FAs in CF:
In CF the fatty acid disturbances are known since the sixties [6,7] 
Different causes have been proposed. First of all, the historical 
fat-free diet could induce essential FA deficiencies. However, 
dietary advice has changed dramatically and disturbances in 
the FA profile are still present. Malabsorption and malnutrition 
could cause increased losses and beta-oxidation for energy 
production, resulting in an essential FA deficiency. However, FA 
disturbances are also present in pancreatic sufficient patients 
and in well-nourished patients. Due to the presence of double 
bonds essential FAs are extremely sensitive for oxidation. The 
more double bonds present, the more vulnerable the FA. An 
increased oxidative stress has been described in CF induced 
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by tissue inflammation and infection. A key role could also be 
attributed to the defective glutathione transport of the CFTR 
protein.  However, improvement of the anti-oxidant status was 
not able to normalize the fatty acid abnormalities.
Finally phospholipase A2, the key enzyme responsible for FA 
release from membrane phospholipids, is abnormally regulated 
in CF. The release of AA by phospholipase A2 is a rate limiting 
step in the production of pro-inflammatory eicosanoids.
These data are probably linked to the overall pro-inflammatory 
condition in CF. 
The interest in the FA status of CF patients increased since the 
report by Freedman et al. They demonstrated the same FA 
disturbances in CF mice and were able to reverse the symptoms 
using pharmaceutical doses of DHA.
In a cross-sectional study the FA status was determined in 
104 CF patients from our CF centre [8]. Eight patients were 
pancreatic sufficient, 15 had liver disease and 13 had diabetes. 
They were divided into two groups according to genotype 
(group A contained patients with two mutations resulting in 
absence of functional CFTR protein and group B contained 
patients with at least one mutation resulting in decreased 
protein function or the mutations with unknown effect on the 
protein). No differences of age, nutritional status, pulmonary 
function or serum vit E concentration were seen between the 
2 groups. Pancreatic sufficiency was only present in the less 
severe mutations (group B). Consequently their caloric intake 
was also significantly lower.
In the ″6 FAs class the differences between the total CF patient 
group and the healthy controls are: lower plasma phospholipid 
LA, increased DHGLA and docosapentaenoic acids. In the ″3 
fatty acid class lower DHA is observed. 
As seen in other essential FA deficiencies, the observed essential 
FA deficiencies induce an increased Mead acid formation, the 
elongation-desaturation product of the ″9 FAs. However, the 
observed FA abnormalities are always less pronounced for less 
severe mutations (group B). 
The only clinical parameter influencing the FA status was the 
presence of liver disease. The CF patients with liver disease 
have an even more pronounced decrease of their DHA, even 
compared to patients of the same genotype.
There was a weak association between serum vit E and 
plasma phospholipid DHA, probably pointing to increased DHA 
oxidation, in presence of a suboptimal anti-oxidant status. 
Since the observed FA disturbances could negatively influence 
the clinical outcome of the CF patients by promoting inflammation, 
an intervention study was performed. DHA is chosen as the FA 
to be supplemented, since Freedman described normalisation 
of the symptoms observed in CF mice treated with this FA. Our 
study was double blind placebo controlled, and was performed 
in delta F 508 homozygous patients without liver disease [9]. 
This genotype subgroup was chosen since we wanted only 
severe mutations to be included. During a full year they had to 
take either the DHA rich algal oil or sunflower seed oil. Of the 17 
patients included, there was one drop out due to Clostridium 
colitis. There were no relevant clinical differences between the 
groups at any time point.
The fasting plasma phospholipid concentrations were not 
different at the start and they displayed the same disturbances as 
described in the fatty acid genotype study. DHA supplementation, 
increases significantly its plasma PL levels. The ratio of the 
omega 6 phospholipid-AA over the omega 3 phospholipid-
DHA, pointing to the proinflammatory fatty acid profile of the 
CF patient, decreased significantly by supplementation. The 
other important finding was the increased of EPA, caused by 
retroconversion of DHA to EPA.  
Also phospholipid docosapentaenoic acid Mead acids 
decreased, proving the better DHA status with supplementation. 
Finally there was a decrease of the ″-6 phospholipid DHGLA 
and AA, probably induced by the inhibitory effect of DHA on the 
delta 6 and delta 5 desaturase activity.
From our observations we can conclude that it is possible 
to shift the FA profile of CF patients to less pro-inflammatory 
profiles. In contrast to the spectacular results of Freedman in 
CF mice, no clinical benefits could be observed in this small 
study group. 
Conclusion :
As a general conclusion from our studies we have established 
normal serum Zn values in our country to be lower than the 
literature data. Compared to local controls CF patients as a total 
group, do not have significantly lower serum Zn concentrations 
as. However there is a subgroup of 40% at diagnosis and 16% 
of the older CF patients falling below references. The decrease 
in IAP could also reflect this deficiency.
The factors influencing the FA status are linked to genotype 
severity and liver disease and should therefore get special 
attention in future FA studies.
On the question of DHA improving clinical outcomes, no 
definite answer could be given. Despite the observed the fatty 
acid shifts, no clinical differences could be observed between 
our treated and placebo patients.
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